Rapidly Establishing an Ultra-Cold Supply Chain of Vaccines in Israel: Evidence for the Efficacy of Inoculation to Mitigate the COVID-19 Pandemic
Author:
Naor Michael1ORCID, Pinto Gavriel David2, Davidov Pini23ORCID, Abdrbo Lina2
Affiliation:
1. School of Business Administration, Hebrew University, Jerusalem 9190501, Israel 2. Industrial Engineering and Management, Azrieli College of Engineering, Jerusalem 9103501, Israel 3. UNEC Cognitive Economics Center, Azerbaijan State University of Economics, Baku AZ1001, Azerbaijan
Abstract
The agenda of this research was to investigate how to mitigate the spread of coronaviruses by rapidly establishing an ultra-cold supply chain of vaccines. Data analysis was conducted by linear regression utilizing a dataset publicly available from the Israel Ministry of Health regarding the daily rates of people vaccinated, tested, hospitalized, etc., since the start of the pandemic. The data provide statistical evidence for the efficacy of the Pfizer vaccines in diminishing a wide variety of disease factors, such as the number of patients who were lightly, moderately, or severely sick, and daily deaths, as well as the rate of spread (R-ratio) and number/percentage of people infected. Insightfully, the data corroborate how the first and second doses of the vaccines were able to decrease the wave of COVID-19, which hit Israel in January 2021, while the booster third dose was able to diminish a subsequent COVID-19 wave occurring in Israel in July 2021.
Funder
Azrieli College of Engineering–Jerusalem Research Fund
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference35 articles.
1. Sinha, A., Bernardes, E., Calderon, R., and Wuest, T. (2021). Digital Supply Networks, McGraw Hill-Ascent Audio. 2. World Health Organization (2022). Operational Guidance on Establishing an Ultra-Cold Chain System in Support of the Pfizer-BioNTech COVID-19 Vaccine Rollout, 1 February 2022 (No. WHO/2019-nCoV/UCC_systems/Pfizer-BioNTech_vaccine/2022.1), World Health Organization. 3. A single dose of recombinant VSV-∆ G-spike vaccine provides protection against SARS-CoV-2 challenge;Tamir;Nat. Commun.,2020 4. Yahalom-Ronen, Y., Erez, N., Fisher, M., Tamir, H., Politi, B., Achdout, H., Melamed, S., Glinert, I., Weiss, S., and Cohen-Gihon, I. (2022). Neutralization of SARS-CoV-2 variants by rVSV-ΔG-spike-elicited human sera. Vaccines, 10. 5. Digital health nation: Israel’s global big data innovation hub;Balicer;Lancet,2017
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|